OxFORD Asset Management LLP lowered its position in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 42.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 68,086 shares of the company’s stock after selling 50,409 shares during the quarter. OxFORD Asset Management LLP owned about 0.16% of Global Blood Therapeutics worth $1,862,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. BlackRock Inc. boosted its holdings in Global Blood Therapeutics by 4,675.5% in the 1st quarter. BlackRock Inc. now owns 2,618,847 shares of the company’s stock worth $96,503,000 after acquiring an additional 2,564,008 shares during the period. Perceptive Advisors LLC boosted its holdings in Global Blood Therapeutics by 23.3% in the 1st quarter. Perceptive Advisors LLC now owns 3,858,978 shares of the company’s stock worth $142,203,000 after acquiring an additional 730,000 shares during the period. Vanguard Group Inc. boosted its holdings in Global Blood Therapeutics by 40.1% in the 1st quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock worth $93,451,000 after acquiring an additional 726,366 shares during the period. Redmile Group LLC boosted its holdings in Global Blood Therapeutics by 195.3% in the 1st quarter. Redmile Group LLC now owns 934,343 shares of the company’s stock worth $34,431,000 after acquiring an additional 617,943 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in Global Blood Therapeutics in the 1st quarter worth approximately $15,149,000. Institutional investors and hedge funds own 86.07% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/oxford-asset-management-llp-decreases-stake-in-global-blood-therapeutics-inc-gbt/1617485.html.

Global Blood Therapeutics, Inc. (NASDAQ GBT) opened at 32.35 on Friday. Global Blood Therapeutics, Inc. has a 12 month low of $13.35 and a 12 month high of $41.15. The firm’s market capitalization is $1.41 billion. The firm has a 50 day moving average price of $28.61 and a 200-day moving average price of $29.62.

Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.06. During the same period last year, the business posted ($0.58) earnings per share. On average, equities analysts forecast that Global Blood Therapeutics, Inc. will post ($2.44) EPS for the current year.

In other Global Blood Therapeutics news, Director Deval L. Patrick sold 27,053 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $29.69, for a total value of $803,203.57. Following the sale, the director now owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jung Choi sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $30.00, for a total value of $90,000.00. Following the completion of the sale, the insider now directly owns 140,055 shares in the company, valued at approximately $4,201,650. The disclosure for this sale can be found here. Insiders sold a total of 36,053 shares of company stock worth $1,073,204 in the last ninety days. Insiders own 5.30% of the company’s stock.

A number of research firms have weighed in on GBT. Morgan Stanley restated an “overweight” rating and issued a $56.00 price target (up previously from $51.00) on shares of Global Blood Therapeutics in a report on Friday. BidaskClub upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Cowen and Company restated an “outperform” rating and issued a $83.00 price target on shares of Global Blood Therapeutics in a report on Monday, August 14th. ValuEngine upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Finally, J P Morgan Chase & Co restated an “overweight” rating and issued a $46.00 price target (up previously from $44.00) on shares of Global Blood Therapeutics in a report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $55.73.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.